Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11945808-B2

Patent

Publication Date

2024-04-02

Expiration Date


Abstract

Substituted cyclohexyl chemical entities of Formula (I):wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

Core Innovation

The invention relates to substituted cyclohexyl chemical entities as NOP receptor inhibitors, including compounds described by Formula (I) and sub-formulas (Ia–If) having variable substituents. The compounds include substituted cyclohexyl scaffolds with stereochemical features such as cis and trans configurations, and the disclosure includes pharmaceutically acceptable salts and related chemical forms for the Formula (I) compounds.

The described chemical entities are provided as NOP (nociceptin/orphanin FQ receptor) inhibitors intended to modulate and inhibit NOP signaling. The scope includes solvates, hydrates, polymorphs, tautomers, prodrugs, metabolites, isotopes, and therapeutically effective amount concepts, and the compounds are framed as treating conditions involving NOP signaling in both CNS and peripheral settings.

The therapeutic context is stated in terms of treatment of neurological disorders, mental and psychiatric disorders, pain disorders, and related cognitive and movement disorders. The disclosure also links NOP modulation to neuroplasticity, neuroprotection, and neurogenesis.

Claims Coverage

The independent claims cover three treatment method categories: neurological disorders, mental and psychiatric disorders, and pain disorders. They administer an effective amount of one of a specified set of substituted cyclohexyl compounds or pharmaceutically acceptable salts, with the inventive features centered on the selected compound group and the disorder category being treated.

Treating neurological disorders with a selected cyclohexyl compound

Administering to a patient in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt thereof, selected from a group consisting of five enumerated substituted cyclohexyl chemical entities, including N-methyl oxane-4-carboxamides and tetrahydro-2H-pyran-4-carboxamides with cis/trans stereochemical variants and specified aryl substitution patterns.

Treating mental and psychiatric disorders with a selected cyclohexyl compound

Administering to a patient in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt thereof, selected from a group consisting of five enumerated substituted cyclohexyl chemical entities with cis/trans stereochemical variants and specified aryl substitution patterns.

Treating pain disorders with a selected cyclohexyl compound

Administering to a patient in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt thereof, selected from a group consisting of five enumerated substituted cyclohexyl chemical entities with cis/trans stereochemical variants and specified aryl substitution patterns.

Across the independent claims, the central inventive concept is treating targeted disorder categories by administering an effective amount of one of a specifically enumerated set of substituted cyclohexyl NOP receptor inhibitor compounds or pharmaceutically acceptable salts, where the compounds are constrained by defined structural scaffolds and cis/trans stereochemistry.

Stated Advantages

Treating neurological disorders by inhibition or modulation of NOP signaling.

Treating mental and psychiatric disorders through NOP signaling modulation or inhibition.

Treating pain disorders through NOP signaling modulation or inhibition.

Supporting neuroplasticity, neuroprotection, and neurogenesis-related outcomes.

Providing intended uses including metabolic studies, reaction kinetic studies, detection and imaging techniques, and radioactive therapies.

Documented Applications

Metabolic studies and reaction kinetic studies.

Detection and imaging techniques, including radioactive therapies.

Therapeutic modulation or inhibition of NOP signaling for CNS and peripheral disorders, including neurological and neurodegenerative diseases, depression, schizophrenia, pain, and other peripheral inflammatory, metabolic, and organ disorders.

Augmentation of cognitive and motor training and neuroplasticity, neuroprotection, and neurogenesis.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.